Kairos Pharma signs deal for Celyn Therapeutics' CL-273 [Yahoo! Finance]
Kairos Pharma, Ltd. (KAPA)
Company Research
Source: Yahoo! Finance
CL-273 is a reversible, investigational, wild-type-sparing pan epidermal growth factor receptor (EGFR) small molecule inhibitor developed using an AI-based drug discovery platform. The asset specifically targets resistant mutations that arise during treatment with EGFR tyrosine kinase inhibitors, addressing drug resistance in non-small cell lung cancer (NSCLC) with EGFR mutations. The acquisition aims to expedite the development of next-generation targeted therapies for EGFR mutant NSCLC patients globally. Kairos Pharma CEO John Yu said: “The signing of binding terms to acquire CL-273 represents a pivotal step in building Kairos Pharma's next generation of targeted therapies for EGFR mutant lung cancer. “This transaction is expected to be value accretive. CL-273's AI-designed, wild-type sparing pan EGFR profile positions it as a potentially best-in-class asset in a large, fast-growing $16.2bn lung cancer market with significant unmet needs due to the development of resistance
Show less
Read more
Impact Snapshot
Event Time:
KAPA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KAPA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KAPA alerts
High impacting Kairos Pharma, Ltd. news events
Weekly update
A roundup of the hottest topics
KAPA
News
- Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics [Yahoo! Finance]Yahoo! Finance
- Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn TherapeuticsBusiness Wire
- Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics [Yahoo! Finance]Yahoo! Finance
- Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn TherapeuticsBusiness Wire
- Kairos Pharma to Present at 3rd Annual DealFlow Discovery ConferenceBusiness Wire
KAPA
Sec Filings
- 3/2/26 - Form 8-K
- 2/26/26 - Form 8-K
- 1/26/26 - Form EFFECT
- KAPA's page on the SEC website